King's College Hospital Nhs Foundation Trust

TC BioPharm's TCB008 Shows Promise in Phase 2b ACHIEVE Trial for Acute Myeloid Leukemia

6 months ago

• TC BioPharm's ACHIEVE Phase 2b trial evaluates TCB008 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS/AML). • The trial's Cohort A, focusing on relapsed/refractory AML patients, has completed dosing with a favorable safety profile and some achieving stable disease. • Cohort B, involving patients in remission with minimal residual disease, has seen its first patient complete dosing, with recruitment ongoing. • Preliminary data from the ACHIEVE trial supports the positive safety profile of TCB008, with no drug-related adverse events reported.

LYTENAVA Receives NICE Recommendation for Wet AMD Treatment in the UK

6 months ago

• LYTENAVA (bevacizumab gamma) has been recommended by NICE for treating wet AMD, marking the first positive reimbursement decision worldwide for this ophthalmic formulation. • This decision allows LYTENAVA to be available on the NHS and for Independent Sector Providers, offering a cost-effective anti-VEGF treatment option for approximately 40,000 new wet AMD patients each year in the UK. • Outlook Therapeutics anticipates launching LYTENAVA in the UK in the first half of 2025 and is progressing with pricing and reimbursement processes in EU countries for subsequent launches. • LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for treating wet AMD in the EU and UK, holding an initial 10 years of market exclusivity.

Semaglutide Shows Promise in MASH Treatment, Phase III Trial Results

6 months ago

• Semaglutide significantly improved liver fibrosis and MASH resolution compared to placebo in a Phase III trial, marking a potential breakthrough in treatment. • The ESSENCE trial demonstrated that semaglutide led to higher rates of steatohepatitis resolution without worsening fibrosis (63% vs 34%) and fibrosis improvement (37% vs 23%). • Patients on semaglutide achieved a dual secondary endpoint of both MASH resolution and liver fibrosis improvement at twice the rate of those on placebo (33% vs 16%). • Novo Nordisk plans to seek regulatory approval for semaglutide in MASH based on these positive results, potentially expanding treatment options for this liver disease.

King's College Hospital to Pilot Ondine Biomedical's Steriwave for HAI Prevention

7 months ago

• King's College Hospital will pilot Ondine Biomedical's Steriwave technology as part of a quality improvement initiative to prevent hospital-acquired infections (HAIs). • Steriwave uses a light-activated agent to eliminate infection-causing pathogens in a rapid, five-minute treatment, offering an alternative to antibiotics. • Mid Yorkshire Teaching NHS Trust adopted Steriwave as standard of care for preventing surgical site infections in hip and knee surgery patients in March 2024. • Steriwave's accessibility has increased across England and Wales after its addition to the NHS Supply Chain in June 2024, facilitating broader adoption.

Ponatinib Dose-Ranging Study Shows Efficacy in Chronic-Phase CML Patients

4 years ago

A phase 2 trial evaluating ponatinib in chronic-phase chronic myeloid leukemia (CP-CML) patients resistant to prior tyrosine kinase inhibitors (TKIs) demonstrated significant efficacy across three starting doses. The study highlighted a novel, response-based dose-reduction strategy, with the 45 mg starting dose showing optimal benefit/risk outcomes when reduced to 15 mg upon achieving a response.